Maverix Medical Acquires Cirrus Bio for Lung Cancer Diagnostics.

 


Maverix Medical, a lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., has acquired Cirrus Bio for an undisclosed amount.


Cirrus Bio focuses on multiomic solutions for disease diagnosis and management, with a focus on early detection. The founders, David Mallery and Scott Morris, have a history of successful ventures in the medical field.


With this acquisition, Maverix has also launched Maverix Dx, a diagnostic division that will focus on developing tools for lung cancer. David Mallery and Scott Morris will lead this division, focusing on new technologies and strategic investments.


According to Duke Rohlen, Executive Chairman of Maverix Medical, this acquisition will provide the technology and expertise needed to improve early detection of lung cancer, ultimately transforming patient care.


Cirrus is the second major acquisition for Maverix, following Serpex Medical, which focuses on steerable technologies for lung tissue biopsy and therapy delivery. Serpex will continue to operate under Maverix Med Device.


More Informationhttps://www.techdogs.com/tech-news/pr-newswire/maverix-medical-closes-acquisition-of-cirrus-bio-as-foundation-for-diagnostics-platform-in-lung-cancer

Comments

Popular posts from this blog

Aon Unveils $350M Program for Ukraine Recovery

TECNO CAMON 20 Premier 5G and PHANTOM V Flip 5G Secure German Design Awards 2024

Lion Energy Unveils 10W Solar Panel for Portable Power